Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis

Chua, Terence; Saxena, Akshat; Chu, Francis; Butler, S.; Quinn, Richard; Glenn, Derek; Morris, David
April 2011
International Journal of Clinical Oncology;Apr2011, Vol. 16 Issue 2, p125
Academic Journal
Background: Resection of hepatocellular carcinoma (HCC) is potentially curative; however, recurrence is common. To date, few or no effective adjuvant therapies have been adequately investigated. This study evaluates the efficacy of adjuvant iodine-131-lipiodol after hepatic resection through the experience of a single-center hepatobiliary service of managing this disease. Patients and methods: All patients who underwent hepatic resection for HCC and received adjuvant iodine-131-lipiodol between January 1991 and August 2009 were selected for inclusion into the experimental group. A group composed of patients treated during the same time period without adjuvant iodine-131-lipiodol was identified through the unit's HCC surgery database for comparison. The endpoints of this study were disease-free survival and overall survival. Results: Forty-one patients who received adjuvant iodine-131-lipiodol after hepatic resection were compared with a matched group of 41 patients who underwent hepatic resection only. The median disease-free and overall survival were 24 versus 10 months ( P = 0.032) and 104 versus 19 months ( P = 0.001) in the experimental and control groups, respectively. Rates of intrahepatic-only recurrences (73 vs. 37%; P = 0.02) and surgical and nonsurgical treatments for recurrences (84 vs. 56%; P = 0.04) were higher in the experimental group compared to the control group. Conclusion: The finding of this study corroborates the current evidence from randomized and nonrandomized trials that adjuvant iodine-131-lipiodol improves disease-free and overall survival in patients with HCC after hepatic resection. The lengthened disease-free survival after adjuvant iodine-131-lipiodol allows for further disease-modifying treatments to improve the overall survival.


Related Articles

  • High Expression of CCL20 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma after Curative Resection. Ding, Xiangjiu; Wang, Kexin; Wang, Hui; Zhang, Guangyong; Liu, Yajing; Yang, Qingyun; Chen, Weijie; Hu, Sanyuan // Journal of Gastrointestinal Surgery;Apr2012, Vol. 16 Issue 4, p828 

    Introduction: Chemokine ligand 20 (CCL20) plays an important role in the carcinogenesis, invasion, and progression of malignancies. This study aimed to investigate the prognostic significance of CCL20 in patients with hepatocellular carcinoma (HCC) after curative resection. Methods: Expression...

  • Adjuvant Iodine-125 Brachytherapy for Hepatocellular Carcinoma after Complete Hepatectomy: A Randomized Controlled Trial Chen, Kaiyun; Xia, Yong; Wang, Hanning; Xiao, Fanglian; Xiang, Guoan; Shen, Feng // PLoS Clinical Trials;Feb2013, Vol. 8 Issue 2, p1 

    Background: Tumor recurrence is a major problem after curative resection of hepatocellular carcinoma (HCC). The current study evaluated the effects of adjuvant iodine-125 (125I) brachytherapy on postoperative recurrence of HCC. Methodology/Principal Findings: From July 2000 to June 2004,...

  • Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature. Lee, Jacqueline; Corman, Marvin // Journal of Gastrointestinal Surgery;Jan2009, Vol. 13 Issue 1, p150 

    Introduction: Tumors arising from the anal canal are rare, comprising 1.5% of all gastrointestinal tumors in the USA. The vast majority of these anal cancers are epidermoid (cloacogenic/basaloid and squamous cell carcinomas), while adenocarcinomas reportedly occur 5% to 19% of the...

  • Survival After Anatomic Resection Versus Nonanatomic Resection for Hepatocellular Carcinoma: A Meta-Analysis. Chen, Jinggui; Huang, Kai; Wu, Jianghong; Zhu, Huiyan; Shi, Yingqiang; Wang, Yanong; Zhao, Guangfa // Digestive Diseases & Sciences;Jun2011, Vol. 56 Issue 6, p1626 

    Background and Objectives: To compare the effect on survival of anatomic resection (AR) versus nonanatomic resection (NAR) in patients with hepatocellular carcinoma (HCC) from all published comparative studies in the literature. Methods: Databases, including Pubmed, Embase, the Cochrane Library,...

  • Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors. Rutkowski, Piotr; Przybył, Joanna; Zdzienicki, Marcin // Molecular Diagnosis & Therapy;Feb2013, Vol. 17 Issue 1, p9 

    On the basis of the recently published results of a clinical trial comparing 12 and 36 months of imatinib in adjuvant therapy for gastrointestinal stromal tumors (GISTs), which demonstrated clinical benefit of longer imatinib treatment in terms of delaying recurrences and improving overall...

  • Prognostic impact of treatment modalities on patients with single nodular recurrence of hepatocellular carcinoma. Masaki Ueno; Kazuhisa Uchiyama; Satoru Ozawa; Takayuki Nakase; Naoki Togo; Shinya Hayami; Hiroki Yamaue // Surgery Today;Aug2009, Vol. 39 Issue 8, p675 

    Abstract Purpose  To evaluate the prognostic impact of various therapeutic modalities, such as repeat hepatectomy, ablation therapy, and transcatheter arterial chemoembolization (TACE) therapy, used to treat single nodular recurrent hepatocellular carcinoma (HCC). ...

  • Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence? Yu, Ming-Chin; Chan, Kun-Ming; Lee, Chen-Fang; Lee, Yun-Shien; Eldeen, Firas; Chou, Hong-Shiue; Lee, Wei-Chen; Chen, Miin-Fu; Eldeen, Firas Zahr // Journal of Gastrointestinal Surgery;Aug2011, Vol. 15 Issue 8, p1440 

    Backgrounds: Surgical resection remains the first line of treatment for earlier stages of hepatocellular carcinoma (HCC), and it offers the best prognosis for long-term survival. Nevertheless, the recurrence rates after resection are still high in reports. Therefore, it is still...

  • The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. Liang-He Yu; Nan Li; Shu-Qun Cheng // International Journal of Hepatology;2011, p1 

    Hepatocellular carcinoma (HCC) is a highly prevalent and lethal cancer worldwide; despite the curative treatment for HCC, the rate of tumor recurrence after hepatectomy remains high. Tumor recurrence can occur early (<2 years) or late (>2 years) as metastases or de novo tumors. Several tumor...

  • Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib. Barbier, L.; Muscari, F.; Le Guellec, S.; Pariente, A.; Otal, P.; Suc, B. // International Journal of Hepatology;2011, p1 

    Background. Sorafenib is amolecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma in Child A patients. Aims. To address the question of sorafenib as neoadjuvant treatment. Methods. We describe the cases of 2 patients who had surgery after sorafenib. Results....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics